The plasma fraction market has witnessed significant growth and innovation, with increasing demand for plasma-derived therapies addressing a wide range of medical conditions. This article explores the current market trends, segmental insights, and recent developments that are shaping the future of plasma-derived medicines.
The global plasma fraction market was valued at US$ 32.75 billion in 2023 and is projected to reach US$ 72.86 billion by 2034, growing at a CAGR of 7.54% from 2024 to 2034. This expansion is largely driven by the rising demand for plasma-derived medicines used in treating conditions like rabies, tetanus, shock, and trauma. As these life-threatening diseases continue to pose challenges, the need for effective therapeutic solutions derived from plasma is growing, fueling the market’s rapid development.
Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5304
By Type
In 2023, the immunoglobulin segment led the market, capturing the highest share. Plasma-derived immunoglobulin plays a pivotal role in the treatment of autoimmune inflammatory diseases, especially in conditions where the body requires recovery after an infectious attack like COVID-19. Immunoglobulins are essential for treating rare conditions, such as primary immunodeficiency, where they often represent the only viable treatment option.
The coagulation factors segment is anticipated to grow at the fastest pace during the forecast period. These products are crucial for treating blood clotting disorders such as hemophilia and Von Willebrand’s disease, leading to the increased demand for plasma-derived therapies in these areas.
By Application
The hospital segment dominated the plasma fraction market in 2023, thanks to the extensive use of plasma protein to treat a range of conditions in hospital settings. Plasma proteins are vital in managing trauma, burns, animal bites, shocks, major surgeries, hepatitis, RH incompatibility, organ transplants, pediatric HIV, and liver diseases.
Meanwhile, the retail pharmacy segment is expected to experience the fastest growth during the projected period. This growth is driven by a steady rise in human plasma donations and an increasing number of patients eligible for plasma-derived therapies, enhancing both supply and retail sales.
Dr. Ranjeet S. Ajmani, CEO of Aegros Asia, outlined a bold vision to transform plasma fractionation across Asia and other developing regions. His focus is on creating sustainable plasma fractionation models using the HeamaFrac process, addressing the critical issue of over 2 million liters of plasma being wasted annually in Asia. Through partnerships with blood centers, regulators, and local and international organizations, Aegros aims to provide consistent access to safe plasma-derived medicines and improve the quality of life for patients in these regions.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fraction-market-sizing
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5304
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More